Literature DB >> 31707225

Doxorubicin-doxorubicin conjugate prodrug as drug self-delivery system for intracellular pH-triggered slow release.

Jiagen Li1, Xinming Li1, Peng Liu2.   

Abstract

Drug content and releasing rate are the main determining factors for the drug delivery systems (DDSs). Here, doxorubicin dimer (D-DOXcar) was synthesized as drug-drug conjugate prodrug with high drug content of 86%, via an acid-triggered hydrolysable carbamate linker. The prodrug nanoparticles (D-DOXcar-NP) with different diameters were prepared as drug self-delivery system (DSDS) for intracellular pH-triggered slow release. They showed size- and concentration-dependent pH-triggered slow DOX release. For the D-DOXcar-sNP with smaller diameter, the cumulative release ratio reached 25.6% at pH 5.0 within 60 h. The MTT results demonstrated that the proposed DSDS showed similar tumor inhibition regardless of carboxylesterases, and an enhanced anti-tumor efficacy on the HepG2 cells in comparison with the free DOX.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Acid-triggered; Carbamate linker; Doxorubicin; Drug self-delivery system; Drug-drug conjugate; Slow drug release

Mesh:

Substances:

Year:  2019        PMID: 31707225     DOI: 10.1016/j.colsurfb.2019.110608

Source DB:  PubMed          Journal:  Colloids Surf B Biointerfaces        ISSN: 0927-7765            Impact factor:   5.268


  3 in total

1.  Regulation of drug release performance using mixed doxorubicin-doxorubicin dimer nanoparticles as a pH-triggered drug self-delivery system.

Authors:  Jiagen Li; Xinming Li; Pengwei Xie; Peng Liu
Journal:  J Pharm Anal       Date:  2021-03-09

Review 2.  Stimulus-responsive self-assembled prodrugs in cancer therapy.

Authors:  Xiao Dong; Rajeev K Brahma; Chao Fang; Shao Q Yao
Journal:  Chem Sci       Date:  2022-03-18       Impact factor: 9.825

Review 3.  Research Progress of Conjugated Nanomedicine for Cancer Treatment.

Authors:  Bin Zhao; Sa Chen; Ye Hong; Liangliang Jia; Ying Zhou; Xinyu He; Ying Wang; Zhongmin Tian; Zhe Yang; Di Gao
Journal:  Pharmaceutics       Date:  2022-07-21       Impact factor: 6.525

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.